Improving human papillomavirus (HPV) testing in the cervical cancer elimination era : The 2021 HPV LabNet international proficiency study
(2022) In Journal of Clinical Virology 154.- Abstract
Background: Proficient Human Papillomavirus (HPV) genotyping services are essential to support HPV and cervical cancer elimination strategies, in particular to support HPV vaccine research. Objectives: To perform a global HPV genotyping proficiency study, with evaluation in relation to previous proficiency studies. Study design: The proficiency panel contained 44 coded samples (40 samples containing one or more purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) in human DNA, 1 human DNA control and 3 DNA extraction controls). Proficiency required detection of both single and multiple infections of 50 International Units of HPV 16/18, of 500 genome equivalents for other HPV types and no false positivity. Results:... (More)
Background: Proficient Human Papillomavirus (HPV) genotyping services are essential to support HPV and cervical cancer elimination strategies, in particular to support HPV vaccine research. Objectives: To perform a global HPV genotyping proficiency study, with evaluation in relation to previous proficiency studies. Study design: The proficiency panel contained 44 coded samples (40 samples containing one or more purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) in human DNA, 1 human DNA control and 3 DNA extraction controls). Proficiency required detection of both single and multiple infections of 50 International Units of HPV 16/18, of 500 genome equivalents for other HPV types and no false positivity. Results: One hundred and thirty-two laboratories submitted 211 datasets. Most assays used (182/211 datasets) were commercially available. An all-time high of 75% of the datasets were 100% proficient. One or more false positives were found in 17.5% of datasets. Among laboratories who participated in the 2019 proficiency study, full proficiency increased from 25% in 2019 to 60% in 2021. The high overall proficiency was mostly attributable to a large number of new laboratories, which used similar assays. Conclusions: The worldwide deterioration in comparability and reliability of HPV testing found in 2019 is now reversed and an overall increase in proficiency is found.
(Less)
- author
- Arroyo Mühr, Laila Sara ; Eklund, Carina ; Lagheden, Camilla ; Forslund, Ola LU ; Robertsson, Karin Dahlin and Dillner, Joakim
- organization
- publishing date
- 2022-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cancer eradication, Cervical cancer, Human papillomavirus, International standards, Quality assurance
- in
- Journal of Clinical Virology
- volume
- 154
- article number
- 105237
- publisher
- Elsevier
- external identifiers
-
- pmid:35820294
- scopus:85133928248
- ISSN
- 1386-6532
- DOI
- 10.1016/j.jcv.2022.105237
- language
- English
- LU publication?
- yes
- id
- 6357e425-1d04-4956-941d-b1487c4f2b51
- date added to LUP
- 2022-09-15 14:35:37
- date last changed
- 2024-04-14 15:30:15
@article{6357e425-1d04-4956-941d-b1487c4f2b51,
abstract = {{<p>Background: Proficient Human Papillomavirus (HPV) genotyping services are essential to support HPV and cervical cancer elimination strategies, in particular to support HPV vaccine research. Objectives: To perform a global HPV genotyping proficiency study, with evaluation in relation to previous proficiency studies. Study design: The proficiency panel contained 44 coded samples (40 samples containing one or more purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) in human DNA, 1 human DNA control and 3 DNA extraction controls). Proficiency required detection of both single and multiple infections of 50 International Units of HPV 16/18, of 500 genome equivalents for other HPV types and no false positivity. Results: One hundred and thirty-two laboratories submitted 211 datasets. Most assays used (182/211 datasets) were commercially available. An all-time high of 75% of the datasets were 100% proficient. One or more false positives were found in 17.5% of datasets. Among laboratories who participated in the 2019 proficiency study, full proficiency increased from 25% in 2019 to 60% in 2021. The high overall proficiency was mostly attributable to a large number of new laboratories, which used similar assays. Conclusions: The worldwide deterioration in comparability and reliability of HPV testing found in 2019 is now reversed and an overall increase in proficiency is found.</p>}},
author = {{Arroyo Mühr, Laila Sara and Eklund, Carina and Lagheden, Camilla and Forslund, Ola and Robertsson, Karin Dahlin and Dillner, Joakim}},
issn = {{1386-6532}},
keywords = {{Cancer eradication; Cervical cancer; Human papillomavirus; International standards; Quality assurance}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Journal of Clinical Virology}},
title = {{Improving human papillomavirus (HPV) testing in the cervical cancer elimination era : The 2021 HPV LabNet international proficiency study}},
url = {{http://dx.doi.org/10.1016/j.jcv.2022.105237}},
doi = {{10.1016/j.jcv.2022.105237}},
volume = {{154}},
year = {{2022}},
}